The UK and US have concluded a important bilateral deal that will ensure zero import taxes on British drug products entering the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to increase funding on medicines through the National Health Service (NHS). This pledge ensures that tariffs on these vital products will stay at zero for a period of 36 months.
This agreement is in response to recent warnings to dramatically increase import taxes on patented pharmaceutical imports, with increases mentioned as high as double the cost.
"This arrangement with the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue equity to U.S.–U.K. medicine commerce," a statement said.
Trade Impact
Drugs represent one of the the United Kingdom's most significant export categories to the America, which is easily the primary buyer for major British pharmaceutical firms.
Statistics indicate that in the one-year period to the end of September, the UK exported drugs totaling over eleven billion pounds to the US. This amount accounted for 17.4% of total UK exports in that timeframe.
"This deal safeguards jobs, increases investment and facilitates the UK to emerge as a international leader for biotech and pharma," a minister commented.
Specific UK Commitments
The deal involves several key changes from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase overall public funding on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Payback Limit: The sum manufacturers must pay back to the NHS to prevent overspending will be limited at 15%. In the past, repayments exceeded 20%.
Broader Context
This agreement follows a ongoing tension between the sector and the UK government over drug pricing and regulatory access.
The disagreement were exacerbated by claims that American patients were charged a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while substantial expansions have been directed toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its spending on drugs had declined as a share of its resources over the past decade.
